Results 21 to 30 of about 2,874 (159)

Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections [PDF]

Journal of Clinical Medicine, 2019
This study reports the integrated analysis of two phase III studies of meropenem-vaborbactam in the treatment of acute bacterial infections. Targeting Antibiotic Non-Susceptible Gram-Negative Organisms (TANGO) I compared the clinical efficacy and tolerability of meropenem-vaborbactam and piperacillin-tazobactam in the treatment of complicated urinary ...
Chih-Cheng Lai, Chi-Chung Chen, Hung-Jen Tang   +2 more
openaire   +3 more sources

Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination [PDF]

Expert Review of Anti-infective Therapy, 2020
infections due to carbapenem-resistant Enterobacterales (CRE) constitute a worldwide threat and are associated with significant mortality, especially in fragile patients, and costs. Meropenem-vaborbactam (M/V) is a combination of a group 2 carbapenem with a novel cyclic boronic acid-based β-lactamase inhibitor which has shown good efficacy against KPC ...
Novelli A, Del Giacomo P, Rossolini GM, Tumbarello M   +3 more
openaire   +3 more sources

Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections

Infectious Diseases and Therapy, 2020
Plain Language Summary Meropenem-vaborbactam is a new combination antibiotic that was designed specifically for efficacy against bacteria that produce the Klebsiella pneumoniae carbapenemase (KPC) enzyme, which enables resistance to beta-lactam ...
Tanaya Bhowmick, Melvin P. Weinstein
doaj   +1 more source

In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales from patients with intra-abdominal infections: Results of the study for Monitoring Antimicrobial Resistance Trends (SMART) in Taiwan, 2020

Journal of Microbiology, Immunology and Infection, 2023
Background: Multi-drug resistant Enterobacterales is a growing health threat. Imipenem/relebactam and meropenem/vaborbactam, are not clinically used in Taiwan and the susceptibility is lack from routine laboratory tests.
Yu-Lin Lee, Wen-Chien Ko, Po-Ren Hsueh
doaj   +1 more source

New evidence in severe pneumonia: meropenem-vaborbactam

Revista Española de Quimioterapia, 2022
The appearance and spread of new mechanisms of bacterial resistance to antibiotics is a serious health problem. One of the most difficult resistance mechanisms to treat is the production of carbapenemases. Carbapenemase KPC is one of those mechanisms with few therapeutic options.
Forteza Guillot, Maria, Martin Cerezuela, Maria, Ramirez, Paula   +2 more
openaire   +3 more sources

Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations [PDF]

Clinical Infectious Diseases, 2018
Ceftazidime/avibactam and meropenem/vaborbactam are changing the management of invasive infections due to carbapenem-resistant Enterobacteriaceae (CRE), leading to higher rates of clinical cure, decreased mortality, and decreased rates of acute kidney injury compared with colistin-based regimens.
Jason M, Pogue, Robert A, Bonomo, Keith S, Kaye   +2 more
openaire   +2 more sources

Bicyclic Boronates as Potent Inhibitors of AmpC, the Class C β-Lactamase from Escherichia coli

Biomolecules, 2020
Resistance to β-lactam antibacterials, importantly via production of β-lactamases, threatens their widespread use. Bicyclic boronates show promise as clinically useful, dual-action inhibitors of both serine- (SBL) and metallo- (MBL) β-lactamases.
Pauline A. Lang, Anete Parkova, Thomas M. Leissing, Karina Calvopiña, Ricky Cain, Alen Krajnc, Tharindi D. Panduwawala, Jules Philippe, Colin W. G. Fishwick, Peteris Trapencieris, Malcolm G. P. Page, Christopher J. Schofield, Jürgen Brem   +12 more
doaj   +1 more source

In vitro activity of new combinations of β-lactam and β-lactamase inhibitors against the Mycobacterium tuberculosis complex

Microbiology Spectrum, 2023
As meropenem-clavulanic acid is recommended for the treatment of drug-resistant tuberculosis, the repurposing of new carbapenem combinations may provide new treatment options, including oral alternatives.
Elin Economou Lundeberg, Viktoria Andersson, Maria Wijkander, Ramona Groenheit, Mikael Mansjö, Jim Werngren, Teresa Cortes, Ivan Barilar, Stefan Niemann, Matthias Merker, Claudio U. Köser, Lina Davies Forsman   +11 more
doaj   +1 more source

Radical Borylation of Alkyl Bromides by Photoinduced Halogen‐Atom Transfer

Angewandte Chemie, Volume 137, Issue 38, September 15, 2025.
The photoinduced borylation of alkyl bromides via halogen atom transfer is reported. The utility of this strategy is demonstrated with broad functional group tolerance in the borylation of various primary, secondary, and tertiary alkyl bromides. Computational studies provide mechanistic insights into the radical‐chain pathway.
Cullen R. Schull, Matthew J. McGill, Ángel Renteria‐Gómez, Poulami Mukherjee, Samuel B. Tyndall, Aaron H. Shoemaker, Michael R. Wasielewski, Osvaldo Gutierrez, Karl A. Scheidt   +8 more
wiley   +2 more sources

QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics

Frontiers in Microbiology, 2021
QPX7728 is a novel β-lactamase inhibitor (BLI) that belongs to a class of cyclic boronates. The first member of this class, vaborbactam, is a BLI in the recently approved Vabomere (meropenem-vaborbactam).
Olga Lomovskaya, Ruslan Tsivkovski, Dongxu Sun, Raja Reddy, Maxim Totrov, Scott Hecker, David Griffith, Jeffery Loutit, Michael Dudley   +8 more
doaj   +1 more source